Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is expected to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Supernus Pharmaceuticals to post earnings of $0.41 per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $50.84 on Tuesday. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $57.65. The business has a 50 day moving average price of $49.80 and a 200 day moving average price of $47.58. The company has a market capitalization of $2.92 billion, a P/E ratio of -149.53, a P/E/G ratio of 0.64 and a beta of 0.71.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SUPN. Vestcor Inc purchased a new position in shares of Supernus Pharmaceuticals in the 3rd quarter worth about $67,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $55,000. Osaic Holdings Inc. lifted its position in Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after buying an additional 1,328 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $128,000.

Analysts Set New Price Targets

SUPN has been the topic of a number of analyst reports. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. TD Cowen boosted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Stifel Nicolaus upped their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.